Neumora Therapeutics

NMRAPhase 3

Watertown, United StatesFounded 2019neumoratx.com

Neumora Therapeutics aims to transform the treatment of neuropsychiatric and neurodegenerative disorders by developing precision therapies based on biological subtypes. The company's platform integrates data science, neurobiology, and clinical development to match the right drug to the right patient. Its most advanced asset, navacaprant, represents a novel mechanism for depression, with a Phase 3 program underway. Backed by significant venture capital and a high-profile IPO, Neumora is positioned as a leader in the next generation of neuroscience drug development.

Market Cap

$426.5M

Founded

2019

Employees

100-250

Focus

Biotech

NMRA · Stock Price

USD 2.5114.49 (-85.24%)

Historical price data

AI Company Overview

Technology Platform

A data-driven precision neuroscience platform that integrates multi-omics, neuroimaging, and digital biomarkers to deconvolve disease heterogeneity, identify patient subtypes, and match novel therapeutics to specific biological drivers.

Pipeline Snapshot

7 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 2

Opportunities

Neumora's primary growth opportunity lies in successfully launching navacaprant as a novel, non-monoamine based treatment for MDD, specifically targeting anhedonia.

Success would validate its platform, enabling expansion into other neuropsychiatric (e.g., schizophrenia, bipolar depression) and neurodegenerative indications, potentially through internal pipeline advancement and strategic partnerships.

Risk Factors

The key risk is clinical failure of navacaprant in Phase 3, which would severely impact valuation and challenge the company's core platform thesis.

Additional risks include intense competition in depression, regulatory hurdles, future financing needs, and the inherent difficulty of demonstrating efficacy in heterogeneous brain diseases.

Competitive Landscape

Neumora competes with large pharma (J&J, Sage/Biogen, Lundbeck) in depression and agitation in Alzheimer's. Its main differentiation is its data-driven precision approach targeting biological subtypes, particularly for anhedonia in depression, a symptom area with limited effective treatments.

Publications

Patents

Pipeline